Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000905148-25-000941
Filing Date
2025-03-17
Accepted
2025-03-17 20:54:51
Documents
1
Period of Report
2025-03-13

Document Format Files

Seq Description Document Type Size
1 form4.html 4  
1 form4.xml 4 5428
  Complete submission text file 0000905148-25-000941.txt   7154
Mailing Address 8 DAVIS DRIVE SUITE 220 DURHAM NC 27709
Business Address 8 DAVIS DRIVE SUITE 220 DURHAM NC 27709 248-681-9815
Opus Genetics, Inc. (Issuer) CIK: 0001228627 (see all company filings)

EIN.: 113516358 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 37000 GRAND RIVER AVE SUITE 120 FARMINGTON HILLS MI 48335
Business Address
Zaremba Rabourn Amy (Reporting) CIK: 0001832343 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-34079 | Film No.: 25746234